TY - JOUR
T1 - Molecular profile of advanced-stage transitional cell carcinoma of the ovary
AU - Gershenson, D. M.
AU - Baker, V. V.
AU - Price, J. E.
AU - Hung, M. C.
AU - El-Naggar, A. K.
AU - Tortolero-Luna, G.
AU - Silva, E. G.
PY - 1997
Y1 - 1997
N2 - OBJECTIVES: Our purpose was to determine the molecular profile of advanced-stage transitional cell carcinoma in terms of immunostaining for p53, epidermal growth factor receptor and HER-2/neu, deoxyribonucleic acid index, and S-phase fraction and to analyze the prognostic significance of these markers. STUDY DESIGN: Archival paraffin-embedded tissue blocks from 29 advanced stage transitional cell carcinomas were obtained. Selected sections of the primary tumors were immunostained for p53, epidermal growth factor receptor, and HER-2/neu; deoxyribonucleic acid ploidy and S-phase fraction were determined with use of flow cytometry. Clinical information was abstracted from the medical records. Survival times were analyzed according to the life-table methods of Kaplan and Meier, and the statistical significance of the various factors was tested with the log-rank test. The proportional hazards model of Cox was used to identify prognostic factors. RESULTS: Positive immunostaining was observed for p53 in 13 cases (45%), for epidermal growth factor receptor in 14 cases (50%), and for HER-2/neu in 19 cases (55%). Tumors were diploid in 16 cases (55%) and aneuploid in 13 (45%). The S-phase fraction was ≤15% (mean) in 13 cases (45%) and >15% in 16 cases (55%). The median survival for the entire group was 52 months. None of the above variables had a significant effect on survival time. CONCLUSION: Neither immunostaining for p53, epidermal growth factor receptor, and HER- 2/neu nor deoxyribonucleic acid ploidy nor S-phase fraction allowed us to distinguish transitional cell carcinoma from other more common epithelial ovarian cancers. In addition, no prognostic significance was associated with these biomarkers. A study of larger numbers of cases may be more elucidative.
AB - OBJECTIVES: Our purpose was to determine the molecular profile of advanced-stage transitional cell carcinoma in terms of immunostaining for p53, epidermal growth factor receptor and HER-2/neu, deoxyribonucleic acid index, and S-phase fraction and to analyze the prognostic significance of these markers. STUDY DESIGN: Archival paraffin-embedded tissue blocks from 29 advanced stage transitional cell carcinomas were obtained. Selected sections of the primary tumors were immunostained for p53, epidermal growth factor receptor, and HER-2/neu; deoxyribonucleic acid ploidy and S-phase fraction were determined with use of flow cytometry. Clinical information was abstracted from the medical records. Survival times were analyzed according to the life-table methods of Kaplan and Meier, and the statistical significance of the various factors was tested with the log-rank test. The proportional hazards model of Cox was used to identify prognostic factors. RESULTS: Positive immunostaining was observed for p53 in 13 cases (45%), for epidermal growth factor receptor in 14 cases (50%), and for HER-2/neu in 19 cases (55%). Tumors were diploid in 16 cases (55%) and aneuploid in 13 (45%). The S-phase fraction was ≤15% (mean) in 13 cases (45%) and >15% in 16 cases (55%). The median survival for the entire group was 52 months. None of the above variables had a significant effect on survival time. CONCLUSION: Neither immunostaining for p53, epidermal growth factor receptor, and HER- 2/neu nor deoxyribonucleic acid ploidy nor S-phase fraction allowed us to distinguish transitional cell carcinoma from other more common epithelial ovarian cancers. In addition, no prognostic significance was associated with these biomarkers. A study of larger numbers of cases may be more elucidative.
KW - Deoxyribonucleic acid ploidy
KW - Epidermal growth factor receptor
KW - HER-2/neu
KW - P53
KW - Platinum-based chemotherapy
KW - Transitional cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0030872038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030872038&partnerID=8YFLogxK
U2 - 10.1016/S0002-9378(97)70449-6
DO - 10.1016/S0002-9378(97)70449-6
M3 - Article
C2 - 9240594
AN - SCOPUS:0030872038
SN - 0002-9378
VL - 177
SP - 120
EP - 125
JO - American journal of obstetrics and gynecology
JF - American journal of obstetrics and gynecology
IS - 1
ER -